Skip to main content
PMC home page
The Journal of Headache and Pain logoLink to The Journal of Headache and Pain
. 2009 Mar 11;10(3):161–166. doi: 10.1007/s10194-009-0110-x

Plasma calcitonin gene-related peptide concentration is comparable to control group among migraineurs and tension type headache subjects during inter-ictal period

Ravi Gupta 1,✉, Tanzeel Ahmed 2, Basudeb Banerjee 2, Manjeet Bhatia 1
PMCID: PMC3451985  PMID: 19277835

Abstract

Calcitonin gene-related peptide (CGRP) is known to increase during acute attack of migraine and tension type headache (TTH). However, its concentration during inter-ictal period is not known. This may help us to understand the pathophysiology of these headaches. The objectives of this study are to find out the concentration of CGRP in plasma during inter-ictal period among migraineurs and TTH and to compare it with control group through cross-sectional study from headache clinic of a tertiary centre. Study sample comprised of three groups: migraineurs, TTH subjects as well as a healthy control group. Fifty subjects in each group were included after screening for the respective inclusion criteria and exclusion criteria. None of the subjects was blood relatives of other subject. Their venous blood was drawn and plasma was separated to be kept at −70°C. CGRP was analysed with commercially available ELISA kit. Data were analysed with the help of SPSS V 11.0 for Windows. Chi-square, independent sample t test and one-way ANOVA with post hoc Tukey and univariate regression were performed. Plasma CGRP concentration was not different among three diagnostic groups (F = 0.78; P = 0.49). Similarly, plasma CGRP concentration was not different among episodic TTH and chronic TTH groups (t = 0.32; P = 0.97) and comparison of episodic and chronic migraine groups also revealed similar results in this study (1.14 vs. 0.94 ng/ml; P = 0.23). The presence of aura did not affect the inter-ictal CGRP levels among migraineurs (F = 0.16; P = 0.85). In conclusion, this study suggests that migraine and TTH could be episodic disorders and subjects have comparable CGRP levels during inter-ictal period.

Keywords: Migraine, Tension type headache, CGRP, Inter-ictal period

Full Text

The Full Text of this article is available as a PDF (168.5 KB).

Acknowledgments

We are thankful to the Zydus Cadila for helping us in procurement of kits and chemicals used in this study.

Conflict of interest

None.

References

  • 1.Li J, Vause CV, Durham PL. Calcitonin gene-related peptide stimulation of nitric oxide synthesis and release from trigeminal ganglion glial cells. Brain Res. 2008;1196:22–32. doi: 10.1016/j.brainres.2007.12.028. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Thalakoti S, Patil VV, Damodaram S, Vause CV, Langford LE, Freeman SE, Durham PL. Neuron-glia signaling in trigeminal ganglion: implications for migraine pathology. Headache. 2007;47:1008–1023. doi: 10.1111/j.1526-4610.2007.00854.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Ashina M, Bendtsen L, Jensen R, Sakai F, Olesen J. Possible mechanisms of glyceryl-trinitrate-induced immediate headache in patients with chronic tension-type headache. Cephalalgia. 2000;20:919–924. doi: 10.1046/j.1468-2982.2000.00150.x. [DOI] [PubMed] [Google Scholar]
  • 4.Doods H, Arndt K, Rudolf K, Just S. CGRP antagonists: unravelling the role of CGRP in migraine. Trends Pharmacol Sci. 2007;28:580–587. doi: 10.1016/j.tips.2007.10.005. [DOI] [PubMed] [Google Scholar]
  • 5.Edvinsson L. Novel migraine therapy with calcitonin gene-regulated peptide receptor antagonists. Expert Opin Ther Targets. 2007;11:1179–1188. doi: 10.1517/14728222.11.9.1179. [DOI] [PubMed] [Google Scholar]
  • 6.Fusayasu E, Kowa H, Takeshima T, Nakaso K, Nakashima K. Increased plasma substance P and CGRP levels, and high ACE activity in migraineurs during headache-free periods. Pain. 2007;128:209–214. doi: 10.1016/j.pain.2006.09.017. [DOI] [PubMed] [Google Scholar]
  • 7.Sarchielli P, Alberti A, Codini M, Floridi A, Gallai V. Nitric oxide metabolites, prostaglandins and trigeminal vasoactive peptides in internal jugular vein blood during spontaneous migraine attacks. Cephalalgia. 2000;20:907–918. doi: 10.1046/j.1468-2982.2000.00146.x. [DOI] [PubMed] [Google Scholar]
  • 8.Juhasz G, Zsombok T, Modos EA, Olajos S, Jakab B, Nemeth J, et al. NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release. Pain. 2003;106:461–470. doi: 10.1016/j.pain.2003.09.008. [DOI] [PubMed] [Google Scholar]
  • 9.Juhasz G, Zsombok T, Jakab B, Nemeth J, Szolcsanyi J, Bagdy G. Sumatriptan causes parallel decrease in plasma calcitonin gene-related peptide (CGRP) concentration and migraine headache during nitroglycerin induced migraine attack. Cephalalgia. 2005;25:179–183. doi: 10.1111/j.1468-2982.2005.00836.x. [DOI] [PubMed] [Google Scholar]
  • 10.Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med. 2004;350:1073–1075. doi: 10.1056/NEJMoa030505. [DOI] [PubMed] [Google Scholar]
  • 11.Petersen KA, Lassen LH, Birk S, Lesko L, Olesen J. BIBN4096BS antagonizes human alpha calcitonin gene related peptide-induced headache and extracerebral artery dilatation. Clin Pharmacol Ther. 2005;77:202–213. doi: 10.1016/j.clpt.2004.10.001. [DOI] [PubMed] [Google Scholar]
  • 12.Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J. CGRP may play a causative role in migraine. Cephalalgia. 2002;22:54–61. doi: 10.1046/j.1468-2982.2002.00310.x. [DOI] [PubMed] [Google Scholar]
  • 13.Gallai V, Sarchielli P, Floridi A, Franceschini M, Codini M, Glioti G, et al. Vasoactive peptide levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalalgia. 1995;15:384–390. doi: 10.1046/j.1468-2982.1995.1505384.x. [DOI] [PubMed] [Google Scholar]
  • 14.Coppola G, Pierelli F, Schoenen J. Is the cerebral cortex hyperexcitable or hyperresponsive in migraine? Cephalalgia. 2007;27:1427–1439. doi: 10.1111/j.1468-2982.2007.01500.x. [DOI] [PubMed] [Google Scholar]
  • 15.Ashina M, Bendtsen L, Jensen R, Schifter S, Olesen J. Evidence for increased plasma levels of calcitonin gene-related peptide in migraine outside of attacks. Pain. 2000;86:133–138. doi: 10.1016/S0304-3959(00)00232-3. [DOI] [PubMed] [Google Scholar]
  • 16.Bellamy JL, Cady RK, Durham PL. Salivary levels of CGRP and VIP in rhinosinusitis and migraine patients. Headache. 2006;46:24–33. doi: 10.1111/j.1526-4610.2006.00294.x. [DOI] [PubMed] [Google Scholar]
  • 17.Tvedskov JF, Lipka K, Ashina M, Iversen HK, Schifter S, Olesen J. No increase of calcitonin gene-related peptide in jugular blood during migraine. Ann Neurol. 2005;58:561–568. doi: 10.1002/ana.20605. [DOI] [PubMed] [Google Scholar]
  • 18.Ashina M, Bendtsen L, Jensen R, Schifter S, Jansen-Olesen I, Olesen J. Plasma levels of calcitonin gene-related peptide in chronic tension-type headache. Neurology. 2000;55:1335–1340. doi: 10.1212/wnl.55.9.1335. [DOI] [PubMed] [Google Scholar]
  • 19.Ashina M. Calcitonin gene-related peptide in tension-type headache. Sci World J. 2002;2:1527–1531. doi: 10.1100/tsw.2002.808. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Bigal ME, Lipton RB, Holland PR, Goadsby PJ. Obesity, migraine, and chronic migraine: possible mechanisms of interaction. Neurology. 2007;68:1851–1861. doi: 10.1212/01.wnl.0000262045.11646.b1. [DOI] [PubMed] [Google Scholar]
  • 21.Zelissen PM, Koppeschaar HP, Lips CJ, Hackeng WH. Calcitonin gene-related peptide in human obesity. Peptides. 1991;12:861–863. doi: 10.1016/0196-9781(91)90147-H. [DOI] [PubMed] [Google Scholar]
  • 22.Lind H, Brudin L, Lindholm L, Edvinsson L. Different levels of sensory neuropeptides (calcitonin gene-related peptide and substance P) during and after exercise in man. Clin Physiol. 1996;16:73–82. doi: 10.1111/j.1475-097X.1996.tb00557.x. [DOI] [PubMed] [Google Scholar]
  • 23.Headache Classification Subcommittee of the International Headache Society The International Classification of Headache Disorders. Cephalalgia. 2004;24(Suppl 1):1–151. doi: 10.1111/j.1468-2982.2003.00824.x. [DOI] [PubMed] [Google Scholar]
  • 24.Bartolini M, Baruffaldi R, Paolino I, Silvestrini M. Cerebral blood flow changes in the different phases of migraine. Funct Neurol. 2005;20:209–211. [PubMed] [Google Scholar]
  • 25.Ashina M, Bendtsen L, Jensen R, Olesen J. Nitric oxide induced headache in patients with chronic tension-type headache. Brain. 2000;123:1830–1837. doi: 10.1093/brain/123.9.1830. [DOI] [PubMed] [Google Scholar]
  • 26.Akerman S, Williamson DJ, Kaube H, Goadsby PJ. Nitric oxide synthase inhibitors can antagonize neurogenic and calcitonin gene-related peptide induced dilation of dural meningeal vessels. Br J Pharmacol. 2002;137:62–68. doi: 10.1038/sj.bjp.0704842. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Ashina M, Lassen LH, Bendtsen L, Jensen R, Olesen J. Effect of inhibition of nitric oxide synthase on chronic tension- type headache: a randomised crossover trial. Lancet. 1999;353:287–289. doi: 10.1016/S0140-6736(98)01079-4. [DOI] [PubMed] [Google Scholar]
  • 28.Jansen I, Uddman R, Ekman R, Olesen J, Ottosson A, Edvinsson L. Distribution effects of neuropeptide Y, vasoactive intestinal peptide, substance P and calcitonin gene-related peptide in human middle meningeal arteries: comparison with cerebral and temporal arteries. Peptides. 1992;13:527–536. doi: 10.1016/0196-9781(92)90084-G. [DOI] [PubMed] [Google Scholar]
  • 29.Jansen I, Uddman R, Hocherman M, Ekman R, Jensen K, Olesen J, et al. Localization and effects of neuropeptide Y, vasoactive intestinal polypeptide, substance P and calcitonin gene-related peptide in human temporal arteries. Ann Neurol. 1986;20:496–501. doi: 10.1002/ana.410200409. [DOI] [PubMed] [Google Scholar]
  • 30.Smith D, Hill RG, Edvinsson L, Longmore J. An immunocytochemical investigation of human trigeminal nucleus caudalis: CGRP, substance P and 5-HT1D-receptor immunoreactivities are expressed by trigeminal sensory fibers. Cephalalgia. 2002;22:424–431. doi: 10.1046/j.1468-2982.2002.00378.x. [DOI] [PubMed] [Google Scholar]
  • 31.Ashina M. Neurobiology of chronic tension-type headache. Cephalalgia. 2004;24:161–172. doi: 10.1111/j.1468-2982.2003.00644.x. [DOI] [PubMed] [Google Scholar]
  • 32.Mazzotta G, Sarchielli P, Gaggioli A, Gallai V. Study of pressure pain and cellular concentration of neurotransmitters related to nociception in episodic tension type headache patients. Headache. 1997;37:565–571. doi: 10.1046/j.1526-4610.1997.3709565.x. [DOI] [PubMed] [Google Scholar]
  • 33.Jensen R, Rasmussen BK, Pedersen B, Olesen J. Muscle tenderness and pressure pain thresholds in headache. A population study. Pain. 1993;52:193–199. doi: 10.1016/0304-3959(93)90131-8. [DOI] [PubMed] [Google Scholar]
  • 34.Bendtsen L. Central sensitization in tension type headache—possible pathophysiological mechanisms. Cephalalgia. 2000;20:486–508. doi: 10.1046/j.1468-2982.2000.00070.x. [DOI] [PubMed] [Google Scholar]
  • 35.Lance JW, Goadsby PJ. Mechanism and management of headache. Philadelphia: Elsevier; 2005. [Google Scholar]
  • 36.Gangula PR, Lanlua P, Wimalawansa S, Supowit S, DiPette D, Yallampalli C. Regulation of calcitonin gene-related peptide expression in dorsal root ganglia of rats by female sex steroid hormones. Biol Reprod. 2000;62:1033–1039. doi: 10.1095/biolreprod62.4.1033. [DOI] [PubMed] [Google Scholar]
  • 37.Stevenson JC, MacDonald DWR, Warren RC. Increased concentration of calcitonin gene-related peptide during normal human pregnancy. Br Med J. 1986;293:1329–1330. doi: 10.1136/bmj.293.6558.1329. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from The Journal of Headache and Pain are provided here courtesy of BMC

RESOURCES